This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of lymphoma subtypes.
- Details the most current management across the spectrum of lymphoma subtypes
- Expert contributors from across the US and Canada
- Multidisciplinary coverage and emphasis on emerging therapeutic options, cutting edge developments and clinical research with near-term potential in clinical management
Emerging Cancer Therapeutics is an invited review publication providing a thorough analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence; current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year, Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.
- Hodgkin Lymphoma
- Peripheral T-Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Aggressive B Cell Lymphomas
- Other Indolent NHLs
- Autologous SCT
- Allogeneric SCT
- Non-SCT Salvage Therapy
About the Guest Editors
John Sweetenham, MD, Professor of Medicine, Vice Chair of Research, Taussig Cancer Institute, Cleveland Clinic
Jame Abraham, West Virginia University.